EUVIMEDEUVIMED entdecken
Klinische StudieVideo/AudioOpen Access · CC BY-NC 4.0

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

Brett King, Jennifer Soung, Christos Tziotzios, Lidia Rudnicka, Pascal Joly, Melinda Gooderham, Rodney Sinclair, Natasha A Mesinkovska, Carle Paul, Yankun Gong, Susan D Anway, Helen Tran und 3 weitere

American Journal of Clinical Dermatology · 2024-03 · 25 (2) · 299-314

DOI: 10.1007/s40257-024-00846-3 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift American Journal of Clinical Dermatology, online erschienen am 23.01.2024. Verfasst von Brett King und 14 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Alopecia Areata, Antineoplastic Agents, Tryptamines. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The ALLEGRO phase 2a and 2b/3 studies demonstrated that ritlecitinib, an oral JAK3/TEC family kinase inhibitor, is efficacious at doses of ≥ 30 mg in patients aged ≥ 12 years with alopecia areata (AA). OBJECTIVE: The objective of this study was to evaluate the safety of ritlecitinib in an integrated analysis of four studies in AA. METHODS: Two cohorts were analyzed: a placebo-controlled and an all-exposure cohort. Proportions and study size-adjusted incidence rates (IRs) of adverse events (AEs) of interest and laboratory abnormalities are reported. RESULTS: In the placebo-controlled cohort (n = 881; median exposure: 169 days), the proportion of ritlecitinib-treated patients with AEs was 70.2-75.4% across doses versus 69.5% in the placebo group; serious AEs occurred in 0-3.2% versus 1.9% for the placebo. A total of 19 patients permanently discontinued due to AEs (5 while receiving the placebo). In the all-exposure cohort (n = 1294), median ritlecitinib exposure was 624 days [2091.7 total patient-years (PY)]. AEs were reported in 1094 patients (84.5%) and serious AEs in 57 (4.4%); 78 (6.0%) permanently discontinued due to AEs. The most common AEs were headache (17.7%; 11.9/100 PY), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive test (15.5%; 9.8/100 PY), and nasopharyngitis (12.4%; 8.2/100 PY). There were two deaths (breast cancer and acute respiratory failure/cardiorespiratory arrest). Proportions (IRs) were < 0.1% (0.05/100 PY) for opportunistic infections, 1.5% (0.9/100 PY) for herpes zoster, 0.5% (0.3/100 PY) for malignancies (excluding nonmelanoma skin cancer), and 0.2% (0.1/100 PY) for major adverse cardiovascular events. CONCLUSIONS: Ritlecitinib is well tolerated with an acceptable safety profile up to 24 months in patients aged ≥ 12 years with AA (video abstract and graphical plain language summary available). TRIAL REGISTRIES: ClinicalTrials.gov: NCT02974868 (date of registration: 11/29/2016), NCT04517864 (08/18/2020), NCT03732807 (11/07/2018), and NCT04006457 (07/05/2019).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataAntineoplastic AgentsTryptaminesHumansCarbazolesJanus Kinase 3Protein Kinase InhibitorsSARS-CoV-2Treatment Outcome

Substanzen

Antineoplastic AgentsCarbazolesfrovatriptanJAK3 protein, humanJanus Kinase 3Protein Kinase InhibitorsTryptamines

Autor:innen und Institutionen

  • Yale School of Medicine, New Haven, CT, USA.
  • Southern California Dermatology, Santa Ana, CA, USA.
  • St John's Institute of Dermatology, King's College London, London, UK.
  • Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
  • Rouen University Hospital, INSERM 1234, Normandie University, Rouen, France.
  • Skin Centre for Dermatology, Canada Probity Medical Research, Waterloo, ON, Canada.

Förderung

  • NCATS NIH HHS
  • Pfizer

Zitieren

APA

King, B., Soung, J., Tziotzios, C., Rudnicka, L., Joly, P., Gooderham, M., Sinclair, R., Mesinkovska, N. A., Paul, C., Gong, Y., Anway, S. D., Tran, H., Wolk, R., Zwillich, S. H., & Lejeune, A. (2024). Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. American Journal of Clinical Dermatology, 25(2), 299-314. https://doi.org/10.1007/s40257-024-00846-3

Vancouver

King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et al. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. American Journal of Clinical Dermatology. 2024;25(2):299-314. doi:10.1007/s40257-024-00846-3

BibTeX
@article{King2024,
  author = {King, Brett and Soung, Jennifer and Tziotzios, Christos and Rudnicka, Lidia and Joly, Pascal and Gooderham, Melinda and Sinclair, Rodney and Mesinkovska, Natasha A and Paul, Carle and Gong, Yankun and Anway, Susan D and Tran, Helen and Wolk, Robert and Zwillich, Samuel H and Lejeune, Alexandre},
  title = {Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program},
  journal = {American Journal of Clinical Dermatology},
  year = {2024},
  volume = {25},
  number = {2},
  pages = {299--314},
  doi = {10.1007/s40257-024-00846-3}
}
Kostenlos starten →